Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3971297 · 2 trials · 6 indications
Part A and F: A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module
Part B, C, D, E, \& G: A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module
Part F: PK: AUC of LY3971297
Part F: PK: Cmax of LY3971297
| Arm | Type | Description |
|---|---|---|
| LY3971297 Part A Cohort 1 | EXPERIMENTAL | LY3971297 administered subcutaneously (SC) |
| Placebo Part A Cohort 1 | PLACEBO_COMPARATOR | Placebo administered SC |
| LY3971297 Part A Cohort 2 | EXPERIMENTAL | LY3971297 administered SC |
| Placebo Part A Cohort 2 | PLACEBO_COMPARATOR | Placebo administered SC |
| LY3971297 Part A Cohort 3 | EXPERIMENTAL | LY3971297 administered SC |
| Placebo Part A Cohort 3 | PLACEBO_COMPARATOR | Placebo administered SC |
| LY3971297 Part A Cohort 4 | EXPERIMENTAL | LY3971297 administered SC |
| Placebo Part A Cohort 4 | PLACEBO_COMPARATOR | Placebo administered SC |
| LY3971297 Part A Cohort 5 | EXPERIMENTAL | LY3971297 administered intravenously (IV) |
| Placebo Part A Cohort 5 | PLACEBO_COMPARATOR | Placebo administered IV |
| LY3971297 Part B | EXPERIMENTAL | LY3971297 administered SC or IV |
| Placebo Part B | PLACEBO_COMPARATOR | Placebo administered SC or IV |
| LY3971297 (Part A) | EXPERIMENTAL | Single ascending doses of LY3971297 administered subcutaneously (SC) in healthy participants |
| LY3971297 (Part B) | EXPERIMENTAL | Multiple ascending doses of LY3971297 administered SC in healthy participants |
| LY3971297 (Part C) | EXPERIMENTAL | Multiple ascending doses of LY3971297 administered SC in healthy Chinese participants |
| LY3971297 (Part D) | EXPERIMENTAL | Multiple ascending doses of LY3971297 administered SC |
| LY3971297 (Part E) | EXPERIMENTAL | Multiple doses of LY3971297 administered SC in healthy Japanese participants |
| Placebo (Part A, B, C, D, E, & G) | PLACEBO_COMPARATOR | Placebo administered SC |
| LY3971297 (Part F) | EXPERIMENTAL | Single doses of LY3971297 administered intravenously (IV) in healthy participants |
| LY3971297 (Part G) | EXPERIMENTAL | Multiple doses of LY3971297 administered SC |
| Name | Type | Description |
|---|---|---|
| LY3971297 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
| LY3971297 IV | DRUG | Administered IV |
Inclusion Criteria: * Are diagnosed with chronic heart failure with New York Heart Association Class II-III (Heart Failure) HF symptomatology at screening and on guideline-directed HF therapy for at least 6 months prior to screening. * Have not changed optimal guideline-directed HF therapy, either ...
LY3971297 is an investigational small molecule being developed by Eli Lilly and Company for the treatment of heart failure, including diastolic and systolic heart failure. It is also being studied in healthy participants with obesity and hypertension to evaluate its safety and tolerability. The drug is currently in Phase 1 clinical development.
LY3971297 is a small molecule, but its specific molecular target has not been disclosed in available information. The drug is being studied for its effects in heart failure and related conditions, but the exact mechanism of action is not publicly detailed at this time.
LY3971297 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the stock exchange under the ticker symbol LLY. The company is conducting Phase 1 clinical trials to evaluate the drug's safety and efficacy in healthy participants and in patients with heart failure.
LY3971297 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety, tolerability, and potential efficacy in humans.
LY3971297 is being studied in two Phase 1 clinical trials. The first trial, NCT06148272, is a study in healthy participants with obesity and hypertension, with an enrollment of 225 participants. The second trial, NCT07547540, is a study in participants with heart failure, including diastolic and systolic heart failure, with an enrollment of 90 participants.
LY3971297 is a unique investigational drug candidate and no alternative names have been reported for it. It is being developed solely by Eli Lilly and Company under this identifier, and there are no known generic or brand names associated with it at this stage of development.